VTYX Q4 2023 Earnings — Ventyx Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

VTYXVentyx Biosciences, Inc.

$1B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$50M

Net Income

-$47M

EPS (Diluted)

$-0.79

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$52M

Free Cash Flow

-$52M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$278M

Total Liabilities

$34M

Stockholders' Equity

$244M

Cash & Equivalents

$52M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$50M	-$39M	-30.5%
Net Income	-$47M	-$35M	-32.8%